Stem cell transplants that are a standard treatment for certain blood cancers are out of reach for many patients. The procedure requires cells from a matched donor, but a match isn’t always available.

Study findings showed 86% of patients had early and sustained neutrophil recovery at 100 days. The Food and Drug Administration (FDA) has approved Omisirge ® (omidubicel-onlv) for adults and pediatric ...

It’s been just over a year since the FDA approved the first engineered cell therapy for the treatment of certain patients with advanced synovial sarcoma, a rare cancer that affects fewer than 1000 ...

A rare but severe stem cell transplant complication that often becomes fatal now has its first FDA-approved treatment, a therapy developed by biotechnology company Omeros. The Christmas Eve regulatory ...

DUBLIN, IE AND LONDON, UK / ACCESS Newswire / December 5, 2025 / Ayrmid Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., a leader in cell therapy innovation announces that it ...

The FDA has approved lisocabtagene maraleucel (Breyanzi, Bristol-Myers Squibb) for relapsed or refractory marginal zone lymphoma (MZL) in adults after at least two prior lines of systemic therapy.

Market OverviewThe global cell and gene therapy market is undergoing rapid and transformative growth, reflecting its increasing importance in modern healthcare.The market is projected to expand at a ...